Charlotte Schubert

Sylvester researchers explore new options for acute myeloid leukemia patients in a new commentary for JAMA Oncology.

In a laboratory near downtown Seattle on the shores of Lake Union, Hetu Kamisetty is helping build what he says is the biotech company of the future.

A clinical study evaluated whether two biomarkers could predict disease recurrence in head and neck cancer patients. The presence of elevated levels of either biomarker in saliva was associated with recurrence risk. Further development of the approach could lead to new ways to predict if cancer will come back.

The NCI recently renewed Sylvester’s designation as the only NCI-designated cancer center in South Florida.

The Sylvester Comprehensive Cancer Center researcher discusses brain tumor vulnerabilities and the use of precision medicine to find cancer cures.

Sylvester researchers will explore a new way to treat one of the deadliest tumor types, pancreatic cancer, with funding from a new grant.

Pancreatic cancer care at Sylvester is tailored to each patient near where they live and provides access to expertise throughout treatment.

Sylvester Comprehensive Cancer Center leads a major global effort to understand risk factors for breast cancer in the Caribbean population.

The Sylvester associate director for translational research connects researchers to help bring scientific findings closer to the clinic.

Sylvester's Craig Moskowitz, M.D., helped design a study that showed improved outcomes for Hodgkin lymphoma patients.